Cargando…
Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort
INTRODUCTION: Glomerular Research And Clinical Experiments—IgA Nephropathy in Indians (GRACE-IgANI) is the first prospective South Asian IgA nephropathy (IgAN) cohort with prespecified objectives, protocolized longitudinal follow-up, and extensive biosample collection. The baseline risk scores predi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820995/ https://www.ncbi.nlm.nih.gov/pubmed/35155869 http://dx.doi.org/10.1016/j.ekir.2021.11.012 |
_version_ | 1784646325857419264 |
---|---|
author | Alexander, Suceena Varughese, Santosh Franklin, Rajanbabu Rebekah, Grace Roy, Sanjeet Yusuf, Sabina Thomas, Athul Eapen, Jeethu Joseph John, Elenjickal Elias Valson, Anna T. David, Vinoi George Daha, Mohamed R. Feehally, John Barratt, Jonathan John, George T. |
author_facet | Alexander, Suceena Varughese, Santosh Franklin, Rajanbabu Rebekah, Grace Roy, Sanjeet Yusuf, Sabina Thomas, Athul Eapen, Jeethu Joseph John, Elenjickal Elias Valson, Anna T. David, Vinoi George Daha, Mohamed R. Feehally, John Barratt, Jonathan John, George T. |
author_sort | Alexander, Suceena |
collection | PubMed |
description | INTRODUCTION: Glomerular Research And Clinical Experiments—IgA Nephropathy in Indians (GRACE-IgANI) is the first prospective South Asian IgA nephropathy (IgAN) cohort with prespecified objectives, protocolized longitudinal follow-up, and extensive biosample collection. The baseline risk scores predicted high risk of kidney disease progression. METHODS: A total of 195 of 201 patients (97%) completed 3-year follow-up in September 2020. All patients received optimized supportive care, and those at high risk of progression were offered systemic corticosteroids. RESULTS: A total of 76 patients (76 of 193, 39.4%) had rapid progression in 3 years (≥5 ml/min per 1.73 m(2) decline in estimated glomerular filtration rate [eGFR] per year). A total of 72 patients (72 of 195, 36.9%) experienced the composite outcome (CO), defined as ≥50% fall in eGFR, eGFR < 15 ml/min per 1.73 m(2), commenced kidney replacement therapy or death, in 3 years. At each scheduled follow-up, achievement of proteinuria level < 1 g/d significantly delayed the time to the CO. The receiver operating characteristic curve of average annual decline in eGFR ≥ 5 ml/min per 1.73 m(2) had 86% sensitivity and 89% specificity for CO in 3 years and had good discrimination from 1 year onwards (area under the curve 0.8, SE 0.04, 95% CI 0.7–0.9, P < 0.0001). The significant predictors of CO by Cox proportional-hazards model were as follows: baseline MEST-T2 score (hazard ratio [HR] 3.3, 95% CI 1.7–6.5, P < 0.001), along with 24-hour urine protein level ≥ 1 g/d (HR 2.1, 95% CI 1.1–3.9, P = 0.02), eGFR < 60 ml/min per 1.73 m(2) (HR 2.9, 95% CI 1.1–7.6, P = 0.03), and rate of eGFR decline ≥ 5 ml/min per 1.73 m(2)/yr (HR 2.7, 95% CI 1.6–4.8, P < 0.001) all measured at 6 months. Mortality was 11 of 195 (5.6%). CONCLUSION: We identified longitudinal clinical variables measured at 6 months and ≥5 ml/min per 1.73 m(2) annual fall in eGFR after kidney biopsy as important predictors for composite outcome in addition to baseline histology. |
format | Online Article Text |
id | pubmed-8820995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-88209952022-02-11 Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort Alexander, Suceena Varughese, Santosh Franklin, Rajanbabu Rebekah, Grace Roy, Sanjeet Yusuf, Sabina Thomas, Athul Eapen, Jeethu Joseph John, Elenjickal Elias Valson, Anna T. David, Vinoi George Daha, Mohamed R. Feehally, John Barratt, Jonathan John, George T. Kidney Int Rep Regional Report INTRODUCTION: Glomerular Research And Clinical Experiments—IgA Nephropathy in Indians (GRACE-IgANI) is the first prospective South Asian IgA nephropathy (IgAN) cohort with prespecified objectives, protocolized longitudinal follow-up, and extensive biosample collection. The baseline risk scores predicted high risk of kidney disease progression. METHODS: A total of 195 of 201 patients (97%) completed 3-year follow-up in September 2020. All patients received optimized supportive care, and those at high risk of progression were offered systemic corticosteroids. RESULTS: A total of 76 patients (76 of 193, 39.4%) had rapid progression in 3 years (≥5 ml/min per 1.73 m(2) decline in estimated glomerular filtration rate [eGFR] per year). A total of 72 patients (72 of 195, 36.9%) experienced the composite outcome (CO), defined as ≥50% fall in eGFR, eGFR < 15 ml/min per 1.73 m(2), commenced kidney replacement therapy or death, in 3 years. At each scheduled follow-up, achievement of proteinuria level < 1 g/d significantly delayed the time to the CO. The receiver operating characteristic curve of average annual decline in eGFR ≥ 5 ml/min per 1.73 m(2) had 86% sensitivity and 89% specificity for CO in 3 years and had good discrimination from 1 year onwards (area under the curve 0.8, SE 0.04, 95% CI 0.7–0.9, P < 0.0001). The significant predictors of CO by Cox proportional-hazards model were as follows: baseline MEST-T2 score (hazard ratio [HR] 3.3, 95% CI 1.7–6.5, P < 0.001), along with 24-hour urine protein level ≥ 1 g/d (HR 2.1, 95% CI 1.1–3.9, P = 0.02), eGFR < 60 ml/min per 1.73 m(2) (HR 2.9, 95% CI 1.1–7.6, P = 0.03), and rate of eGFR decline ≥ 5 ml/min per 1.73 m(2)/yr (HR 2.7, 95% CI 1.6–4.8, P < 0.001) all measured at 6 months. Mortality was 11 of 195 (5.6%). CONCLUSION: We identified longitudinal clinical variables measured at 6 months and ≥5 ml/min per 1.73 m(2) annual fall in eGFR after kidney biopsy as important predictors for composite outcome in addition to baseline histology. Elsevier 2021-11-24 /pmc/articles/PMC8820995/ /pubmed/35155869 http://dx.doi.org/10.1016/j.ekir.2021.11.012 Text en © 2021 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Regional Report Alexander, Suceena Varughese, Santosh Franklin, Rajanbabu Rebekah, Grace Roy, Sanjeet Yusuf, Sabina Thomas, Athul Eapen, Jeethu Joseph John, Elenjickal Elias Valson, Anna T. David, Vinoi George Daha, Mohamed R. Feehally, John Barratt, Jonathan John, George T. Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort |
title | Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort |
title_full | Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort |
title_fullStr | Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort |
title_full_unstemmed | Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort |
title_short | Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort |
title_sort | three-year clinical outcomes of the first south asian prospective longitudinal observational iga nephropathy cohort |
topic | Regional Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820995/ https://www.ncbi.nlm.nih.gov/pubmed/35155869 http://dx.doi.org/10.1016/j.ekir.2021.11.012 |
work_keys_str_mv | AT alexandersuceena threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT varughesesantosh threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT franklinrajanbabu threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT rebekahgrace threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT roysanjeet threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT yusufsabina threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT thomasathul threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT eapenjeethujoseph threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT johnelenjickalelias threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT valsonannat threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT davidvinoigeorge threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT dahamohamedr threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT feehallyjohn threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT barrattjonathan threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort AT johngeorget threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort |